CRVS
Corvus Pharmaceuticals Inc
NASDAQ · Biotechnology
$20.46
+1.40 (+7.35%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 641.17M | 595.25M | 563.38M |
| Net Income | 40.80M | 37.35M | 36.12M |
| EPS | — | — | — |
| Profit Margin | 6.4% | 6.3% | 6.4% |
| Rev Growth | +19.0% | -0.6% | +17.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 584.32M | 492.29M | 527.66M |
| Total Equity | 1.08B | 1.18B | 1.14B |
| D/E Ratio | 0.54 | 0.42 | 0.46 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 52.52M | 47.56M | 47.46M |
| Free Cash Flow | 29.89M | 29.19M | 29.71M |